Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Inclusion Criteria: * Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA ≥ 105 IU/mL at the time of screening. * Subjects must have chronic HCV infection as determined by any of the following: * be anti-HCV (+) for at least 6 months per subject history or medical records * an anti-HCV test, viral load, or genotype \> 6 months ago * In the setting of a recent positive anti-HCV test (\< 6 months), liver biopsy demonstrating chronicity * Subjects must have IL-28b genotype "CC" * Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 36 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2 Exclusion Criteria: * Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days (for small molecules) whichever is longer; or longer if required by local regulations. * Previous treatment, including the use of any investigational agents, for the treatment of HCV infection. * Women of child bearing potential. * Subjects with IL-28b genotype "CT or TT". * ALT γ-GT, and AST must be below 5 x the upper limit of normal (ULN). * Serum bilirubin must not exceed ULN. * The PT (INR) must be within normal limits. * If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to randomization, to rule out any laboratory error. * Use of drugs that inhibit or induce CYP3A4.